If you experience any technical difficulties with this video or would like to make an accessibility-related request, please send a message to [email protected]. Olaf Schneewind, M.D., Ph.D, Professor and Chair of the Department of Microbiology, and Joe Kanabrocki, Ph.D, Biosafety Officer for the Ricketts Biocontainment Laboratory, talk about a new state-of-the-art facility designed to develop new treatments, diagnostic tests and vaccines for emerging infectious diseases. The Howard T. Ricketts Laboratory (HTRL) will house research on microbial agents that are considered either Risk Group 2 (agents that cause mild to moderate symptoms in humans, but are not life threatening) or Risk Group 3 (agents that have the potential to cause lethal human infections, but have at least one effective treatment). The HTRL has been designed and built according to the strictest federal standards and incorporates multiple layers of safety and security to protect laboratory workers and the surrounding environment.